Literature DB >> 21624861

Supporting quality and patient safety in cancer clinical trials.

Stephanie Badalucco1, Kathleen Keane Reed.   

Abstract

Adverse event (AE) reporting is a critical component of all cancer clinical trials, and the National Cancer Institute's Common Terminology Criteria for Adverse Events™ (CTCAE) is the primary system used by clinicians to describe the severity of AEs. The National Cancer Institute's Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) assesses patient self-reports of symptoms using a Web-based system that can be incorporated into all cancer clinical trials. Oncology clinical trial nurses are responsible for the protection and safety of patients enrolled in cancer trials and, therefore, should develop an understanding of PRO-CTCAE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624861     DOI: 10.1188/11.CJON.263-265

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  2 in total

Review 1.  Cancer survivorship research in Europe and the United States: where have we been, where are we going, and what can we learn from each other?

Authors:  Julia H Rowland; Erin E Kent; Laura P Forsythe; Jon Håvard Loge; Lars Hjorth; Adam Glaser; Vittorio Mattioli; Sophie D Fosså
Journal:  Cancer       Date:  2013-06-01       Impact factor: 6.860

2.  Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer.

Authors:  Mohamed Alsharedi; Todd Gress; Jennifer Dotson; Nabiha Elmsherghi; Maria Tria Tirona
Journal:  Med Oncol       Date:  2016-02-16       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.